光谱学与光谱分析
光譜學與光譜分析
광보학여광보분석
SPECTROSCOPY AND SPECTRAL ANALYSIS
2015年
4期
1037-1042
,共6页
郑植元%杜玉枝%张明%于明杰%李岑%杨红霞%赵静%夏政华%魏立新
鄭植元%杜玉枝%張明%于明傑%李岑%楊紅霞%趙靜%夏政華%魏立新
정식원%두옥지%장명%우명걸%리잠%양홍하%조정%하정화%위립신
藏药成方制剂%铅%砷%湿法消化%流动注射氢化物原子吸收光谱法
藏藥成方製劑%鉛%砷%濕法消化%流動註射氫化物原子吸收光譜法
장약성방제제%연%신%습법소화%류동주사경화물원자흡수광보법
Traditional tibetan medicine prescription preparations%Lead%Arsenic%Wet digestion%Flow injection -hydride genera-tion-atomic absorption spectrometry (FI-HAAS)
选择藏族地区常用的四种藏药成方制剂安置精华散、当佐、仁青常觉和七十味珍珠丸作为研究对象,通过优化消化条件和测定条件,探索建立其铅、砷含量测定的湿法消化与流动注射氢化物发生‐原子吸收光谱(FI‐HAAS)联用分析方法,并对其铅砷含量进行精确测定。在优化的工作条件下,铅和砷的检出限分别为:0.067和0.012μg·mL-1;定量限分别为:0.22和0.041μg·mL-1;线性范围分别为:25~1600ng·mL-1(r=0.9995),12.5~800ng·mL-1(r=0.9994);精密度(RSD)分别为:2.0%和3.2%;加标回收率范围分别为:98.00%~99.98%和96.67%~99.87%。四种藏药成方制剂的铅、砷含量测定结果如下,安置精华散中铅砷含量分别为:0.63~0.67和0.32~0.33μg·g-1;当佐为:42.92~43.36和24.67~25.87μg·g-1;仁青常觉为:1611.39~1631.36和926.76~956.52μg·g-1;七十味珍珠丸为:1102.28~1119.27和509.96~516.87μg·g-1。本研究建立了藏药成方制剂中铅、砷检测方法,并测定了四种藏药成方制剂中铅、砷含量,为其在临床安全有效使用提供了参考依据。
選擇藏族地區常用的四種藏藥成方製劑安置精華散、噹佐、仁青常覺和七十味珍珠汍作為研究對象,通過優化消化條件和測定條件,探索建立其鉛、砷含量測定的濕法消化與流動註射氫化物髮生‐原子吸收光譜(FI‐HAAS)聯用分析方法,併對其鉛砷含量進行精確測定。在優化的工作條件下,鉛和砷的檢齣限分彆為:0.067和0.012μg·mL-1;定量限分彆為:0.22和0.041μg·mL-1;線性範圍分彆為:25~1600ng·mL-1(r=0.9995),12.5~800ng·mL-1(r=0.9994);精密度(RSD)分彆為:2.0%和3.2%;加標迴收率範圍分彆為:98.00%~99.98%和96.67%~99.87%。四種藏藥成方製劑的鉛、砷含量測定結果如下,安置精華散中鉛砷含量分彆為:0.63~0.67和0.32~0.33μg·g-1;噹佐為:42.92~43.36和24.67~25.87μg·g-1;仁青常覺為:1611.39~1631.36和926.76~956.52μg·g-1;七十味珍珠汍為:1102.28~1119.27和509.96~516.87μg·g-1。本研究建立瞭藏藥成方製劑中鉛、砷檢測方法,併測定瞭四種藏藥成方製劑中鉛、砷含量,為其在臨床安全有效使用提供瞭參攷依據。
선택장족지구상용적사충장약성방제제안치정화산、당좌、인청상각화칠십미진주환작위연구대상,통과우화소화조건화측정조건,탐색건립기연、신함량측정적습법소화여류동주사경화물발생‐원자흡수광보(FI‐HAAS)련용분석방법,병대기연신함량진행정학측정。재우화적공작조건하,연화신적검출한분별위:0.067화0.012μg·mL-1;정량한분별위:0.22화0.041μg·mL-1;선성범위분별위:25~1600ng·mL-1(r=0.9995),12.5~800ng·mL-1(r=0.9994);정밀도(RSD)분별위:2.0%화3.2%;가표회수솔범위분별위:98.00%~99.98%화96.67%~99.87%。사충장약성방제제적연、신함량측정결과여하,안치정화산중연신함량분별위:0.63~0.67화0.32~0.33μg·g-1;당좌위:42.92~43.36화24.67~25.87μg·g-1;인청상각위:1611.39~1631.36화926.76~956.52μg·g-1;칠십미진주환위:1102.28~1119.27화509.96~516.87μg·g-1。본연구건립료장약성방제제중연、신검측방법,병측정료사충장약성방제제중연、신함량,위기재림상안전유효사용제공료삼고의거。
Four common traditional tibetan medicine prescription preparations “Anzhijinghuasan ,Dangzuo ,Renqingchangjue and Rannasangpei”in tibetan areas were selected as study objects in the present study .The purpose was to try to establish a kind of wet digestion and flow injection‐hydride generation‐atomic absorption spectrometry (FI‐HAAS) associated analysis meth‐od for the content determinations of lead and arsenic in traditional tibetan medicine under optimized digestion and measurement conditions and determine their contents accurately .Under these optimum operating conditions ,experimental results were as fol‐lows .The detection limits for lead and arsenic were 0.067 and 0.012 μg · mL -1 respectively .The quantification limits for lead and arsenic were 0.22 and 0.041 μg · mL -1 respectively .The linear ranges for lead and arsenic were 25~1 600 ng · mL -1 (r=0.999 5) and 12.5~800 ng · mL -1 (r=0.999 4) respectively .The degrees of precision(RSD) for lead and arsenic were 2.0%and 3.2% respectively .The recovery rates for lead and arsenic were 98.00% ~99.98% and 96.67% ~99.87% respectively . The content determination results of lead and arsenic in four traditional tibetan medicine prescription preparations were as fol‐lows .The contents of lead and arsenic in Anzhijinghuasan are 0.63~0.67 μg · g -1 and 0.32~0.33 μg · g -1in Anzhijinghua‐san ,42.92~43.36 μg · g -1 and 24.67~25.87 μg · g -1 in Dangzuo ,1 611.39~1 631.36 μg · g -1 and 926.76~956.52 μg · g -1 in Renqing Changjue ,and 1 102.28~1 119.27μg · g -1 and 509.96~516.87μg · g -1 in Rannasangpei ,respectively .This study established a method for content determination of lead and arsenic in traditional tibetan medicine ,and determined the con‐tent levels of lead and arsenic in four tibetan medicine prescription preparations accurately .In addition ,these results also provide the basis for the safe and effective use of those medicines in clinic .